

## ICMJE DISCLOSURE FORM

**Date:** 2/17/2023

**Your Name:** Otto Maarsingh

**Manuscript Title:** Slapeloosheid: een hardnekkig probleem zonder optimale medicamenteuze strategie

**Manuscript Number (if known):** D7301

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
<b>Time frame: Since the initial planning of the work</b>								
<b>1</b>	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"> </td><td style="height: 20px;"> </td></tr> <tr><td style="height: 20px;"> </td><td style="height: 20px;"> </td></tr> <tr><td style="height: 20px;"> </td><td style="height: 20px;"> </td></tr> </table> <p style="font-size: small; margin-top: 5px;">Click the tab key to add additional rows.</p>						
<b>Time frame: past 36 months</b>								
<b>2</b>	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 30%; padding: 5px;">ZonMw</td> <td style="padding: 5px;">ZonMw, Kennisprogramma Huisartsgeneeskunde (main applicant; € 785,320.00): The diagnostic accuracy of history taking and physical examination for patients with vertigo in general practice: the VERDI study</td> </tr> <tr> <td style="padding: 5px;">ZonMw</td> <td style="padding: 5px;">ZonMw, HGOG (co-applicant; € 249,925.00): Chronic dizziness in general practice: from ineffective anti-vertigo drugs to effective vestibular rehabilitation.</td> </tr> <tr> <td style="padding: 5px;">ZonMw</td> <td style="padding: 5px;">ZonMw, Goed Gebruik Geneesmiddelen (co-applicant; € 1,484,215.00): Comparing antidepressant (AD) tapering strategies</td> </tr> </table>	ZonMw	ZonMw, Kennisprogramma Huisartsgeneeskunde (main applicant; € 785,320.00): The diagnostic accuracy of history taking and physical examination for patients with vertigo in general practice: the VERDI study	ZonMw	ZonMw, HGOG (co-applicant; € 249,925.00): Chronic dizziness in general practice: from ineffective anti-vertigo drugs to effective vestibular rehabilitation.	ZonMw	ZonMw, Goed Gebruik Geneesmiddelen (co-applicant; € 1,484,215.00): Comparing antidepressant (AD) tapering strategies
ZonMw	ZonMw, Kennisprogramma Huisartsgeneeskunde (main applicant; € 785,320.00): The diagnostic accuracy of history taking and physical examination for patients with vertigo in general practice: the VERDI study							
ZonMw	ZonMw, HGOG (co-applicant; € 249,925.00): Chronic dizziness in general practice: from ineffective anti-vertigo drugs to effective vestibular rehabilitation.							
ZonMw	ZonMw, Goed Gebruik Geneesmiddelen (co-applicant; € 1,484,215.00): Comparing antidepressant (AD) tapering strategies							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
			for paroxetine and venlafaxine: the TAPER-AD trial.						
		ZonMw	ZonMw, HGOG (co-applicant; € 249,740.00): Towards improvement of healthcare utilisation and quality of care in elderly first-generation non-western migrant people with dementia or diabetes.						
<b>3</b>	Royalties or licenses	<input checked="" type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>							
<b>4</b>	Consulting fees	<input checked="" type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>							
<b>5</b>	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>							
<b>6</b>	Payment for expert testimony	<input checked="" type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>							
<b>7</b>	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>							
<b>8</b>	Patents planned, issued or pending	<input checked="" type="checkbox"/> <b>None</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.